Histidine

Histidine

SCHEMBL6805147

CSCCC(N)C(N)=O.NC(Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP1A2 P05177 1/20 0.35
GRIA1 P42261 4/20 0.33
GRIA2 P42262 4/20 0.33
GRIA3 P42263 4/20 0.33
GRIA4 P48058 4/20 0.33
CTSC P53634 2/20 0.32
NOS2 P35228 2/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
RNPEP Q9H4A4 1/20 0.32
BHMT Q93088 1/20 0.31
BHMT2 Q9H2M3 1/20 0.31
GRIK1 P39086 2/20 0.31
GRIK2 Q13002 2/20 0.31
GRIK3 Q13003 2/20 0.31
GRIK4 Q16099 2/20 0.31
GRIK5 Q16478 2/20 0.31
ALPI P09923 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL1884290 1.00 SLC7A5 (0.38) SLC7A5CYP3A4CYP1A2GRIA1GRIA2
Histidine SCHEMBL27681989 0.94 CYP3A4 (0.40) SLC7A5CYP3A4CYP1A2GRIA1GRIA2
Histidine SCHEMBL342891 0.94 CYP3A4 (0.40) SLC7A5CYP3A4CYP1A2GRIA1GRIA2
Histidine SCHEMBL342892 0.94 CYP3A4 (0.40) SLC7A5CYP3A4CYP1A2GRIA1GRIA2
Histidine SCHEMBL28650960 0.93 CYP3A4 (0.40) SLC7A5CYP3A4CYP1A2GRIA1GRIA2
Histidine SCHEMBL27729896 0.89 CYP3A4 (0.37) SLC7A5CYP3A4CYP1A2GRIA1GRIA2
Histidine SCHEMBL28888007 0.89 CYP3A4 (0.37) SLC7A5CYP3A4CYP1A2GRIA1GRIA2
Histidine SCHEMBL23362634 0.88 BHMT (0.39) SLC7A5CYP3A4CYP1A2GRIA1GRIA2
Histidine SCHEMBL28942432 0.88 FNTA (0.38) SLC7A5CYP3A4PTGS1
Histidine SCHEMBL23362032 0.88 CYP1A2 (0.42) SLC7A5CYP3A4CYP1A2GRIA1GRIA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358485-A2 METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING VASOACTIVE INTESTINAL PEPTIDE RECEPTORS THE PROCTER & GAMBLE COMPANY (US) 2003-11-05 EP claimed
WO-2002035240-A2 METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING VASOACTIVE INTESTINAL PEPTIDE RECEPTORS THE PROCTER & GAMBLE COMPANY (US) 2002-05-02 WO claimed
US-20230125604-A1 ANTI-PACAP ANTIBODIES AND USES THEREOF H LUNDBECK AS (DK) 2023-04-27 US disclosed
CN-109311977-B Humanized anti-PACAP antibodies and uses thereof H.伦德贝克公司 2022-06-14 CN disclosed
CN-108137677-B anti-PACAP antibodies and uses thereof H.伦德贝克公司 2022-01-25 CN disclosed
CN-108055848-B anti-PACAP antibodies and uses thereof H.伦德贝克公司 2021-10-01 CN disclosed
EP-3718570-A1 PHTHALOCYANINE PROBES AND USES THEREOF LI-COR, INC. (US) 2020-10-07 EP disclosed
US-20200179514-A1 PHTHALOCYANINE PROBES AND USES THEREOF LI-COR, INC. (US) 2020-06-11 US disclosed
US-20200165309-A1 ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center 2020-05-28 US disclosed
EP-3148583-B1 PHTHALOCYANINE PROBES AND USES THEREOF LI COR INC (US) 2020-04-29 EP disclosed
US-10588972-B2 Phthalocyanine probes and uses thereof LI-COR, INC. (US) 2020-03-17 US disclosed
US-9885711-B2 Screening methods XOMA TECHNOLOGY LTD. (US) 2018-02-06 US disclosed
EP-3148583-A1 PHTHALOCYANINE PROBES AND USES THEREOF LI-COR, INC. (US) 2017-04-05 EP disclosed
US-20150374819-A1 PHTHALOCYANINE PROBES AND USES THEREOF LI-COR, INC. (US) 2015-12-31 US disclosed
WO-2015187677-A1 PHTHALOCYANINE PROBES AND USES THEREOF LI-COR, INC. (US) 2015-12-10 WO disclosed
US-20040176298-A1 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors THE PROCTER & GAMBLE COMPANY (US) 2004-09-09 US disclosed
US-6750194-B1 ADMINISTERING TO THE SUBJECT A SAFE AND EFFECTIVE AMOUNT OF A VPAC RECEPTOR AGONIST SELECTED FROM THE GROUP CONSISTING OF RO 25-1553, AND PACAP-38 THE PROCTER & GAMBLE COMPANY 2004-06-15 US disclosed
EP-1358485-A2 METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING VASOACTIVE INTESTINAL PEPTIDE RECEPTORS THE PROCTER & GAMBLE COMPANY (US) 2003-11-05 EP disclosed
WO-2002035240-A2 METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING VASOACTIVE INTESTINAL PEPTIDE RECEPTORS THE PROCTER & GAMBLE COMPANY (US) 2002-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200165309-A1 ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES VIP, HAMP, HM13 SLC7A5 1429/4885CYP3A4 3817/4885CYP1A2 4145/4885
US-20150374819-A1 PHTHALOCYANINE PROBES AND USES THEREOF CD47, PHLPP1, PHLPP2 SLC7A5 255/4885CYP3A4 4730/4885CYP1A2 4852/4885
US-10588972-B2 Phthalocyanine probes and uses thereof CD47, PHLPP1, PHLPP2 SLC7A5 255/4885CYP3A4 4730/4885CYP1A2 4852/4885
US-20200179514-A1 PHTHALOCYANINE PROBES AND USES THEREOF CD47, PHLPP1, PHLPP2 SLC7A5 255/4885CYP3A4 4730/4885CYP1A2 4852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.